AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Nuwellis Postpones Q2 Earnings Release, Conference Call
ByAinvest
Wednesday, Aug 6, 2025 8:18 am ET1min read
• Nuwellis postpones Q2 earnings release and conference call • Requires additional time for valuations and audit procedures • No disagreements with auditor Baker Tilly US, LLP • New conference call scheduled for August 14, 2025 • To be held at 9:00 AM ET via webcast and phone dial-in • Audio archive available after the call on the Nuwellis website
Nuwellis, Inc. has announced the postponement of its Q2 2025 earnings release and conference call. The company requires additional time for valuations and audit procedures, and there are no disagreements with its auditor, Baker Tilly US, LLP. The new conference call is scheduled for August 14, 2025, at 9:00 AM ET. It will be held via webcast and phone dial-in, and an audio archive will be available after the call on the Nuwellis website.The postponement comes as Nuwellis continues to navigate its financial reporting process. The company's Q1 2025 earnings release and conference call were held on April 28, 2025. The Q2 2025 earnings release was initially expected to be released on July 15, 2025, but has now been delayed to accommodate the additional time needed for valuations and audit procedures.
Nuwellis has been actively engaged in its financial reporting process, working closely with its auditor to ensure the accuracy and completeness of its financial statements. The company's commitment to transparency and accurate financial reporting is reflected in its decision to delay the earnings release to ensure that all necessary steps are taken to provide investors with a comprehensive and accurate picture of its financial performance.
The postponement of the Q2 earnings release and conference call is a reminder of the importance of thorough and careful financial reporting. Investors and financial professionals should continue to monitor Nuwellis' progress and await the release of its Q2 2025 earnings report.
References:
[1] https://finance.yahoo.com/news/immunitybio-reports-q2-earnings-release-110000675.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet